Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03704467 · ClinicalTrials.gov registry record · Phase 1
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03704467 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 3 participants.
The verdict
NCT03704467, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
Interventions
- DRUG Carboplatin
- DRUG Avelumab
- DRUG M6620
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-03-04 |
| Est. Completion | 2019-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03704467
The ClinicalTrials.gov registry entry for NCT03704467 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT03704467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03704467 about?
NCT03704467 is a clinical study titled "Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer". The study was to evaluate the efficacy and safety of avelumab in combination with M6620 + carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT03704467?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2019-03-04. Estimated completion is 2019-11-06.
What interventions are being tested in trial NCT03704467?
The interventions under investigation include: Carboplatin (DRUG), Avelumab (DRUG), M6620 (DRUG).
Who is sponsoring clinical trial NCT03704467?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.